2011 - 2015
Located in Cambridgeshire, Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non-clinical or industrial markets. Lumora's easy to deploy and use technology can be employed in fields as diverse as food safety testing and medical diagnostics.
How did we help?
The initial investment assisted the company progress its existing non-clinical licence programme and also to develop the platform for clinical applications. Catapult’s continued support aided the business through commercial launch and subsequent clinical licence deals.
The company was sold to ERBA Diagnostics Mannheim in 2015. This followed shortly after an asset purchase by Roche Diagnostics who acquired Lumora’s proprietary nucleic acid Heat Elution purification technology.
These commercial transactions delivered an excellent return for the Catapult Growth Fund with a 5x cash return.